PBM
FULC icon

Propel Bio Management’s Fulcrum Therapeutics FULC Stock Holding History

Propel Bio Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-750,000
Closed -$4.65M – 23
2024
Q2 		$4.65M Hold
750,000
– – 3.02% 11
2024
Q1 		$7.08M Hold
750,000
– – 4.12% 8
2023
Q4 		$5.06M Buy
+750,000
New +$3.33M 4.2% 6

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Propel Bio Management's FULC Position: Q3 2024 in Review

Propel Bio Management sold out of Fulcrum Therapeutics (FULC) in Q3 2024, closing a stake of 750,000 shares — an estimated $4.65M sold.

Propel Bio Management first reported a position in FULC in Q4 2023 and held it in 3 quarters. The position peaked at $7.08M in Q1 2024. 130 funds tracked by Wall St. Rank hold FULC as of Q3 2024.

  • Propel Bio Management reported no remaining Fulcrum Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Propel Bio Management sold 750,000 Fulcrum Therapeutics shares in Q3 2024, an estimated $4.65M.
  • Propel Bio Management first reported a position in Fulcrum Therapeutics in Q4 2023 and held it in 3 quarters.
  • Propel Bio Management's Fulcrum Therapeutics position peaked at $7.08M in Q1 2024.
  • 130 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2024.

Based on Propel Bio Management's 13F filing for Q3 2024, filed 13 Nov 2024.